Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort.

Pubmed ID: 25401375

Pubmed Central ID: PMC4652650

Journal: JAMA internal medicine

Publication Date: Jan. 1, 2015

MeSH Terms: Humans, Male, Aged, Aged, 80 and over, Hydroxymethylglutaryl-CoA Reductase Inhibitors, United States, Cohort Studies, Practice Guidelines as Topic, Atherosclerosis, Lipids

Grants: HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C

Authors: Ballantyne CM, Coresh J, Folsom AR, Miedema MD, Virani SS, Lopez FL, Blaha MJ

Cite As: Miedema MD, Lopez FL, Blaha MJ, Virani SS, Coresh J, Ballantyne CM, Folsom AR. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med 2015 Jan;175(1):138-40.

Studies:

Atherosclerosis Risk in Communities (ARIC)

Biologic Specimen and Data Repository Information Coordinating Center

Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort.

Abstract